Ubiquitination-Associated Ductal-Fibroblast Crosstalk Shapes Tumor Progression and Prognosis in Pancreatic Ductal Adenocarcinoma.
Saved in:
| Title: | Ubiquitination-Associated Ductal-Fibroblast Crosstalk Shapes Tumor Progression and Prognosis in Pancreatic Ductal Adenocarcinoma. |
|---|---|
| Authors: | Fu Y; Clinical Medical College, Southwest Medical University, Luzhou, China, swmu.edu.cn., Zhou X; Clinical Skills Center, The Affiliated Hospital of Southwest Medical University, Luzhou, China, ahswmu.cn., Jiang L; Clinical Medical College, Southwest Medical University, Luzhou, China, swmu.edu.cn., Zhang S; Department of General Surgery, West China Hospital, Sichuan University, Chengdu, China, scu.edu.cn.; Liver Transplant Center, Transplant Center, West China Hospital, Sichuan University, Chengdu, China, scu.edu.cn., Gu Y; Clinical Medical College, Southwest Medical University, Luzhou, China, swmu.edu.cn., Zhuang Z; First Clinical Medical College, Guangdong Medical University, Zhanjiang, Guangdong, China, gdmu.edu.cn., Huang G; Clinical Medical College, Southwest Medical University, Luzhou, China, swmu.edu.cn., Xu Z; Department of General Surgery (Hepatopancreatobiliary surgery), The Affiliated Hospital of Southwest Medical University, Luzhou, China, ahswmu.cn., Xu P; Department of Pediatric Surgery, The Affiliated Hospital of Southwest Medical University, Luzhou, China, ahswmu.cn., Zhong X; Department of Gastroenterology, Affiliated Hospital, Southwest Medical University, Luzhou, China, swmu.edu.cn. |
| Source: | Human mutation [Hum Mutat] 2026 Apr 30; Vol. 2026, pp. 1665552. Date of Electronic Publication: 2026 Apr 30 (Print Publication: 2026). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Wiley-Liss Country of Publication: United States NLM ID: 9215429 Publication Model: eCollection Cited Medium: Internet ISSN: 1098-1004 (Electronic) Linking ISSN: 10597794 NLM ISO Abbreviation: Hum Mutat Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
